相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Drug hypersensitivity: Pharmacogenetics and clinical syndromes
Elizabeth J. Phillips et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)
Immune pathomechanism of drug hypersensitivity reactions
Werner J. Pichler et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)
Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis
L. Valeyrie-Allanore et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
ALDEN, an Algorithm for Assessment of Drug Causality in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case-Control Analysis
B. Sassolas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes
Manuel Florian Struck et al.
INTENSIVE CARE MEDICINE (2010)
CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis
Esther Morel et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Successful Treatment of Stevens-Johnson Syndrome with Steroid Pulse Therapy at Disease Onset
Yayoi Araki et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2009)
Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study
Maja Mockenhaupt et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel
Sitna Halevy et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR study
Juergen Schneck et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis
Wen-Hung Chung et al.
NATURE MEDICINE (2008)
The ophthalmologic management of acute Stevens-Johnson syndrome
Darren G. Gregory
OCULAR SURFACE (2008)
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
Christine Lonjou et al.
PHARMACOGENETICS AND GENOMICS (2008)
Risk factors for acute generalized exanthematous pustulosis (AGEP) - results of a multinational case-control study (EuroSCAR)
A. Sidoroff et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series
L. W. Yip et al.
ALLERGY (2007)
Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis
Mirjana Ziemer et al.
ARCHIVES OF DERMATOLOGY (2007)
Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis
Sylvia H. Kardaun et al.
ACTA DERMATO-VENEREOLOGICA (2007)
Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis
Sarah Guegan et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics
M Mockenhaupt et al.
NEUROLOGY (2005)
Epidemiology of staphylococcal scalded skin syndrome in Germany
M Mockenhaupt et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2005)
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
SL Hung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IVIg) - Clinical experience to date
O Faye et al.
DRUGS (2005)
Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells
A Nassif et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Toxic epidermal necrolysis: Does immunoglobulin make a difference?
KM Brown et al.
JOURNAL OF BURN CARE & REHABILITATION (2004)
Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis
R Shortt et al.
JOURNAL OF BURN CARE & REHABILITATION (2004)
Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis - A prospective noncomparative study showing no benefit on mortality or progression
N Bachot et al.
ARCHIVES OF DERMATOLOGY (2003)
Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis - Results of an international prospective study
A Auquier-Dunant et al.
ARCHIVES OF DERMATOLOGY (2002)
Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis
JP Fagot et al.
AIDS (2001)
SCORTEN: A severity-of-illness score for toxic epidermal necrolysis
S Bastuji-Garin et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2000)
Toxic epidermal necrolysis and Stevens-Johnson syndrome - Does early withdrawal of causative drugs decrease the risk of death?
I Garcia-Doval et al.
ARCHIVES OF DERMATOLOGY (2000)
分享论文
